文献速递淋巴瘤

慢性淋巴细胞白血病共病图谱:个体共病对治疗、死亡及死因的影响

Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death.
PubMed 文献 · Leukemia · 2021-02-18

该研究利用丹麦全国登记数据,纳入1997-2018年诊断的9170例慢性淋巴细胞白血病(CLL)患者,随访中位5.0年,按改良Charlson共病指数分组并与一般人群匹配对照。结果显示所有研究的共病均与死亡率增加相关,许多共病还与CLL相关或无关的特因死亡率增加相关,共病与感染和心血管疾病死亡相关,老年CLL患者预期寿命显著缩短。

要点

  • 所有共病均与CLL患者死亡率增加独立相关。
  • 共病与感染及心血管疾病死亡增加相关。
  • 老年CLL患者较一般人群预期寿命显著缩短。

核心结论

  • 共病与CLL患者死亡率增加相关,并与感染和心血管疾病死亡相关。
  • 老年CLL患者较一般人群存在显著预期寿命损失。

研究设计与样本

  • 基于丹麦全国登记数据,随访1997-2018年诊断的连续CLL患者至死亡或随访结束。
  • 共纳入9170例CLL患者,中位随访5.0年。

主要发现

  • 所有研究的共病均与死亡率增加独立相关。
  • 许多共病还与CLL相关或无关的特因死亡率增加相关。
  • 共病与感染和心血管疾病死亡增加相关。
  • 老年CLL患者较一般人群预期寿命显著缩短。

临床怎么用

  • 应关注CLL患者的共病评估,尤其老年患者。
  • 共病CLL患者治疗需求和疗效安全性数据不足,临床试验中应予以重视。

局限性

  • 研究基于丹麦登记数据,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Comorbid conditions are highly prevalent in chronic lymphocytic leukemia (CLL), nevertheless, detailed information on the association of specific comorbidities with CLL prognosis is missing. Using Danish, nation-wide registers, we followed consecutive patients from CLL-diagnosis in 1997-2018, until death or end of follow-up. Sub-grouping of comorbidities was defined using a modified Charlson comorbidity index. Patients were matched on sex, date of birth (±1 month), and region of residency with up to ten comparators from the general population. In total, 9170 patients with CLL were included in the study, with a median of 5.0 years of follow-up. All comorbid conditions studied were individually associated with increased mortality, and many also with increased cause-specific mortality, related or unrelated to CLL. Comorbidity correlated with increased mortality from infections and cardiovascular disease. CLL patients, particularly older, had a significant loss of lifetime compared with the general population. This study highlights a large subgroup of comorbid CLL patients with an unmet treatment-need and missing efficacy and safety data on treatment, who are under-prioritized in clinical trials. Also, studies assessing interventions that may provide better tolerability of treatment in older or comorbid patients, with cancer in general, and CLL in particular, are warranted.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Rotbain EC, Niemann CU, Rostgaard K, et al. Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death. Leukemia. 2021. PMID: 33603143. doi:10.1038/s41375-021-01156-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。